Navigation Links
Peripheral Arterial Disease to be Treated With New Medicated Stent in Trial at Montefiore
Date:10/15/2007

New Treatment Could Benefit Millions Who Suffer From Condition

NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- The first trial to test whether medicated, drug-eluting (dispensing), stents can benefit patients who suffer from peripheral arterial disease (PAD) is taking place at Montefiore Medical Center, one of only 80 sites around the world joining in the study.

Medicated, drug-coated stents have been used with great success for the past several years in treating coronary artery disease.

PAD affects more than 10 million Americans, according to the Peripheral Arterial Disease (P.A.D.) Coalition. The disease restricts circulation in blood vessels that lead from the heart to other areas of the body, such as the legs and feet. Often undiagnosed, PAD results in pain when walking and can lead to gangrene and amputation. It also may signal an increased risk for coronary arterial disease and other related circulatory conditions.

"This is an exciting trial since it is the first evaluation of a drug- eluting stent in blood vessels outside the heart," said Evan Lipsitz, MD, chief of Vascular Surgery at Montefiore and principal investigator of the study. "Combining a stent designed to hold blood vessels open to allow blood to flow freely through the vessel, with a medication used to prevent renarrowing, may reduce the development of scar tissue, the primary cause of the stent failure, in the months following balloon angioplasty in leg arteries.

This helps eliminate the need for more invasive treatment, such as bypass surgery," Dr. Lipsitz said.

The stent is coated with paclitaxel, a drug derived from the Pacific yew tree that has been used successfully to reduce the risk of renarrowing of arteries.

The trial is designed to determine the safety and effectiveness of the Zilver(R) PTXTM drug-eluting stent in treating blockages in the femoropoliteal artery, the major artery in the thigh.

Montefiore Medical Center, The Universi
'/>"/>

SOURCE Montefiore Medical Center
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
2. AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at International Congress on Neuropathic Pain
3. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
4. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
5. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
6. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
7. REACH Registry Demonstrates That Multiple Arterial Disease Locations Sharply Increase the Risk of Major CV Events in Outpatients With Atherothrombosis
8. Appendicitis: Evolving Tools to Diagnose a Classic Disease
9. Non-Invasive Diagnostic Tests for Celiac Disease
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2008)... Proteolix, Inc., a,leader in the...hat target,protein degradation pathways in cancer...ta from two ongoing Phase 2 clinical trials of car... the upcoming 50th Annual Meeting of the,American...first in a new class,of specific proteasome inhib...
(Date:11/25/2008)...re-FirstCall/ -- Pharmacyclics, Inc.,(Nasdaq: P...ed a Phase 1,clinical trial with PCI-27483, the c...tor VIIa inhibitor. The trial was conducted in six...ty and pharmacologic effect of,PCI-27483. A singl... dose,response in the International Normalized Ra...
(Date:11/25/2008)...Call/ -- CardioVascular,BioTherapeutics, Inc. (OT...as,dosed the first patient in North America (NA) ...reat patients with severe coronary heart disease. ...nary heart Disease) trial will include,four rando...pproximately 120,patients with severe coronary he...
(Date:11/24/2008)...e/ -- Domino,s Pizza (NYSE: DPZ ), the,recogniz...o raise dough for,the kids of St. Jude Children,s... and Giving campaign. Domino,s customers will have...urchase to benefit the children of St. Jude.,Dona...when ordering online at, www.dominos.com . The ca...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3MyHealthGate Inc Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 27425 1MyHealthGate Inc Joins With LiveActive Chewy Granola Bars to Raise Digestive Health Awareness 27425 2Ohios Regulation of RU 486 Clear and Constitutional Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 27423 1Ohios Regulation of RU 486 Clear and Constitutional Should Be Upheld Argues AUL in Brief Filed Before Ohio Supreme Court 27423 2CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 27421 1CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 27421 2CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 27421 3A Mindful Chocolate Meditation 27418 1A Mindful Chocolate Meditation 27418 2
...care System and,Worker Productivity, SAN DIEGO, Ju...iosciences, Inc. announced today that results from... primary and transient,insomnia were presented thi...ies (APSS) Annual Meeting. APSS highlights show th...uts a significant,strain on the Healthcare System ...
...BUSINESS WIRE)--Jun,13, 2007 - Amgen (NASDAQ:AMGN)...YSE:WYE), today announced the presentation of,addi... Enbrel(R),(etanercept) was maintained with long-t...le rheumatoid arthritis (JRA) who,completed up to ...e,disease of childhood that is sometimes difficult...
Other Medicine Technology:Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 2Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 3Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 4Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 2Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 3Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 4Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 5Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 6Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 7Enbrel Safety Data for up to Eight Years in Patients with Juvenile,Rheumatoid Arthritis Being Presented at EULAR 8
(Date:12/1/2008)...re/ -- In the face of one of the most,severe econ... Health Board of,Directors has approved an invest...d the Sutter Health Retirement Plan. Employee pens...ocks and bonds, have been among the biggest,casua...conservatively,invested, the Sutter Health Retire...
(Date:12/1/2008)...l/ - The Westaim Corporation today announced it ha...of NUCRYST Pharmaceuticals Corp. to consider a ret...ately US$15 million or US$0.80 per share. Westaim ...he value of its 74.5 per cent stake in NUCRYST. Un...,s Board of Directors has 20 days to call a meetin...
(Date:12/1/2008).../ -- ETHICON, Inc., a Johnson & Johnson compa...stiture of its Professional Wound Care business to...saction are not being disclosed. , , Under ...has acquired the Professional Wound Care product p...brands as PROMOGRAN Matrix Wound Dressing, TIELLE ...
(Date:12/1/2008)...swire/ -- Democratic National Committee Chairman H...mmemorating World AIDS Day on its 20th Anniversary...n/prnh/20080519/DNCLOGO ) , , "It,s been 20...e have made strides, much work remains to be done ...lobal strategy. We must focus not only on prevent...
Breaking Medicine News(10 mins):Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3
...alif., "In light of the recent news event where a ...is (XDR-TB) flew on multiple airline flights and ...r rapid identification of MTB and assessment of dr... the disease" said Dr. Nani Dattagupta, Chief Scie...
...N.Y., Over one hundred Long Island AARP members ga...slation before the end of the 2007 Legislative Ses...rugs more affordable and help assure that their ce...took their message directly to their legislators d...
...ta is interested in having a third child, but the ...s autistic condition public . Travolta has not com...s autistic. However, a magazine editor, who inter... the view that if Travolta doesnt shy away from ac...
...the Group of Eight industrialized nations plan to ...fighting the HIV/AIDS pandemic during their upcomi...t week, German Chancellor Angela Merkel's spokespe...n Wednesday, Reuters reports. Wilhelm said details...
Other Medicine News:Health News:Long Island Seniors Rally for Rx Affordable Prescription Drugs and Cell Phone Protections 2Health News:Travolta Maybe Reluctant to Publicaly Discuss About Sons Autism 2Health News:G8 Members To Announce Plans To Increase HIV/AIDS Spending at Summit 2
...e HI VISION 8500 diagnostic ultrasound scanner com... operation for exceptional imaging and functionali...anced techniques for image enhancement and control...nding, wideband pulse-inversion, tissue harmonics,...
... a 2.4mm channel within a 12.1mm insertion tube. ...ultrasound image for improved reliability, an elec... and a 7.5 and 5.0mhz transducer for deeper ultras...or anatomical orientation and vascular evaluation ...
...CTRA 1400C are designed to achieve low daily opera...This system includes automated primary tube sampli...says in a single setup. It also has an integrated ...nce curves and patient sample dilutions to ensure ...
The ACL 7000 coagulation analyzer is the right choice for any laboratory that needs a full range of testing capabilities in a cost-effective system. You'll have access to a broad test menu including
Medicine Products: